

# Index

## Pharmacological Reviews

Volume 31

1979

- Acetylcholine, effect on hypothalamic CRF release and content in vitro (fig.), 261
- Acrosin, inhibitors of, 8
- Adrenergic innervation of kidney, 169
- Adrenergic nervous system, effect on sodium reabsorption and excretion, 170
- Afferent systems, digitalis effects on, 21
- Age, influence on drug metabolism, 243
- Alpha-adrenergic stimulation and blockade, 171
- Amine metabolites, ionization of, and their renal excretion, 201
- Atrial muscle refractory period, role of nervous system on digitalis effect on, 61
- Atrioventricular conduction, role of nervous system in digitalis effect on, 62
- Beta-adrenergic stimulation and blockade, 173
- Bethanechol, effect on hypothalamic CRF release and content in vitro (fig.), 261
- Blood coagulation, plasma kallikrein, and kininogen, 5
- Bönisch, H. See Trendelenburg et al., 179
- Carcinogen metabolism, regiospecificity of cytochrome P-450 in, 290
- Carcinogens, effects in cultured hepatic cells, 205, 218
- Cardiac arrhythmia, role of nervous system in digitalis effect on, 64
- Cardiac output, role of nervous system in digitalis effect on, 54
- Cardiovascular effects of digitalis, role of nervous system in, 52
- Cardiovascular surgery, heparin in, 126, 128
- Catecholamines  
effect on renal tissue cyclic nucleotides, 175  
effect on sodium transport in epithelial tissues, 174  
effect on sodium reabsorption and excretion, 170  
metabolites eliminated from central nervous system, 194  
metabolites, lipophilicity of, 188  
rate constants for efflux of metabolites of, 179, 185  
sodium transport and, in the kidney, 169
- Cells  
intact, factors that influence rates of drug hydroxylation and conjugation in (table), 246  
intact, hepatic drug metabolism in, 229  
whole, mixed-function oxidase study in, 231
- Central nervous system  
catecholamine metabolites eliminated from, 194  
digitalis effects on, 25
- Chlorpromazine effect on corticotrophin releasing factor, 266
- Coagulating gland  
kallikreins in, 9  
kinogenase, 8
- Corticotrophin releasing activity  
detection of, 256  
quantification of, 256
- Corticotrophin releasing factor, 253  
chemical nature of, 254  
control of secretion of, 259  
effects of acetylcholine, nicotine, and bethanechol on hypothalamic release of and content in vitro (fig.), 261  
evidence of, 253  
hypothalamic content after stress (fig.), 260  
mechanism of action, 264  
pharmacology of, 265  
pituitary ACTH content, after stress (fig.), 260  
plasma ACTH concentration, after stress (fig.), 260  
plasma corticosterone concentration, after stress (fig.), 260
- Cyclic nucleotides in renal tissue, effect of catecholamines on, 175
- Cytochrome P-450  
column chromatography of, 289  
estimation by chemical probes, 287  
forms of, from rabbit liver microsomes (table), 283  
from rabbit liver microsomes (table), 283  
from rabbit lung microsomes (table), 283  
genetic studies, 279  
identification and quantification of, in microsomal preparations, 287  
immunological analysis of, 289  
in human liver microsomes, 286; (table), 287  
in mouse liver microsomes, 286  
in rat liver microsomes, 284; (table), 285  
mammalian microsomal, multiplicity of, 277  
multiple forms, 279  
in rabbit microsomes, 282  
multiplicity of  
developmental studies, 279  
induction studies, 278  
inhibition studies, 278  
kinetic studies, 278  
microsomal studies, 278  
number of forms of, 289  
oxidation:reduction state of, in perfused liver, 236  
partial separation of, within the microsomal membrane, 287  
peptide mapping of, 288  
pig kidney and liver microsomes, 286; (table), 286  
purification studies, 279  
regiospecificity of multiple forms of, in drug, mutagen, and carcinogen metabolism, 290  
SDS-gel electrophoresis of, 288  
substrate specificity, control, 279
- Diet, influence on drug metabolism, 243
- Digitalis  
effects on  
afferent systems, 21  
central nervous system, 25  
efferent systems, 30  
electrogenic sodium pump, 51  
neurotransmitters, 41  
postsynaptic membranes, 52  
specific receptor mechanisms, 51  
neurocardiovascular effects of, in therapy of congestive heart failure and cardiac arrhythmias (table), 79  
role of nervous system in  
cardiovascular effects of, 19, 52  
therapeutic cardiovascular actions of, 79  
toxic cardiovascular actions of, 80
- Dopamine, rate constants for efflux of metabolites of, from striatal slices (table), 194
- Dopaminergic stimulation, 174
- Drug conjugation, factors that influence rates of, in intact cells (table), 246

- Drug hydroxylation, factors that influence rates of, in intact cells (table), 246
- Drug metabolism. *See under* Metabolism
- Drugs  
polyelectrolyte. *See* Polyelectrolytes  
transport of, biotransformation reactions and, 235
- Efferent systems, digitalis effects on, 30
- Enzymes  
anionic polyelectrolyte reaction with, 110  
effects of commercial heparin and heparinoids on (table), 111
- Ethanol, effect on drug metabolism, 240
- Gillis, Richard A., and John A. Quest. The role of the nervous system in the cardiovascular effects of digitalis, 19
- Glucocorticoids, effect on corticotrophin releasing factor, 268
- Gluconeogenesis, inhibition of, 234
- Glucuronidation, regulation of, 241
- Glutathione, rate-controlling factors in conjugation of, in intact cells, 242
- Glycolysis, stimulation of, 235
- Glycosaminoglycans, relation to anionic polyelectrolytes, 105
- Graefe, K.-H. *See* Trendelenburg et al., 179
- Heart rate, role of nervous system in digitalis effect on, 60
- Hemorrhage, spontaneous, with heparin, 122
- Henseling, M. *See* Trendelenburg et al., 179
- Heparinoids, chemistry of, 104
- Hepatic. *See also under* Liver
- Hepatic cells  
cultured, drug metabolism in, 205  
effects of carcinogens in, 205
- Heparin  
anionic polyelectrolyte drugs, 99  
anticoagulant action of, 112  
blocking agents for, 121  
chemistry of, 103  
clinical effectiveness  
in cardiovascular surgery, 126  
in thromboembolism, 126  
clinical uses of, 133  
clotting time response, 115  
commercial, pharmacology of, 110  
complexing properties of, 106  
heparin unit and, salts of, 108  
heparinoids and  
actions on cells and tissues, 113  
biological effects of (table), 114  
commercial, effects on enzymes (table), 111  
complex-forming substances (table), 106  
in cardiovascular surgery and diagnosis, 128  
in therapeutics, 125  
in thromboembolism, 129  
in tissues, 137  
monitoring of use of, in therapy, 136  
pharmacokinetics and metabolism, 139  
problem of standardization of, as a drug, 109  
related anionic polyelectrolytes and, in biology, 136  
routes and modes of administration, 117  
spontaneous hemorrhage with, 122  
thrombosis related to clinical effects of, 125  
toxicity of, 124
- Hepatocytes  
in cell culture, drug metabolism in, 233  
intact  
effect of oxygen on drug metabolism in, 236  
factors regulating drug metabolism in, 229  
isolated, drug metabolism in, 233
- Hypertension and renal kallikrein, 7
- Jaques, L. B. Heparins—anionic polyelectrolyte drugs, 99
- Kallikreins  
bioregulatory serine proteases, 11  
cell proliferation and, 10  
functions of, 11  
growth, differentiation, and development, 10  
growth factors and, 10  
homology of, 11  
inhibitors of, 4  
serine proteases with bioregulatory actions, 1  
neoplasia and, 10  
other kininogenases and, 2  
plasma, kininogen, blood coagulation, and, 5  
renal  
hypertension, prostaglandins, and, 7  
renin and, 7  
urinary and, 7  
reproductive system and, 8  
subcellular localization of, 9  
-trypsin inhibitor (Kunitz) polyvalent, in bovine organs, 4
- Kidney  
adrenergic innervation of, 169  
catecholamines and sodium transport in, 169  
kallikreins in, 9  
Kidney microsomes, pig, cytochrome P-450 in, 286; (table), 286
- Kim, Jin K., Stuart L. Linas, and Robert W. Schrier. Catecholamines and sodium transport in the kidney, 169
- Kininogen, 4  
plasma kallikrein, blood coagulation, and, 5
- Kininogenases. *See* Kallikreins
- Leucocytes  
basophilic, mast cells and  
functions of, 145  
properties of, 141
- Linas, Stuart L. *See* Kim et al., 169
- Lipogenesis, inhibition of, 235
- Liver  
mammalian, use of cultured cells for investigation of xenobiotic metabolism, 206  
vertebrate, use of cultured cells for investigation of xenobiotic metabolism, 206
- Liver cells  
carcinogen-induced DNA repair of, in short-term suspension or primary culture (table), 219  
cultured  
effects of carcinogens, mutagens, and toxins on, 218  
microsomal cytochromes of, 213  
monooxygenases of, 212  
properties of transformed, 221; (table), 221  
regulation of xenobiotic metabolism in, 214  
"induction" of microsomal cytochromes and monooxygenase activity in primary culture by xenobiotics, chemicals, cofactors, and hormones (table), 215
- Liver cells. *See also* Hepatic cells and Hepatocytes
- Liver microsomes  
human, cytochrome P-450 in, 286; (table), 287  
mouse, cytochrome P-450 in, 286; (table), 286  
pig, cytochrome P-450 in, 286; (table), 286  
rabbit, cytochrome P-450 from (table), 283  
rat, cytochrome P-450 in, 284; (table), 285
- Lung microsomes, rabbit, cytochrome P-450 from (table), 283

- Mast cells**  
 basophilic leucocytes and  
 functions of, 145  
 properties of, 141
- Metabolism**  
 drug  
 chronic influence of diet, inducing agents, and age, 243  
 effects of carcinogens in cultured hepatic cells, 205  
 intermediary and, in intact cells, interaction (fig.), 230  
 in intact hepatocytes, regulating factors, 229  
 ethanol effect on, 240  
 in hepatocytes in cell culture, 233  
 inhibition by direct binding and inactivation, 236  
 in isolated hepatocytes, 233  
 in perfused organs, 231  
 regiospecificity of cytochrome P-450 in, 290  
 energy, and mixed-function oxidation, relationship, 239  
 heparin, 119  
 intermediary  
 alteration secondary to acute changes in nutrition, relationship  
 with mixed-function oxidation, 235  
 effect of substrates for mixed function oxidation on, 234  
 xenobiotic  
 cultured cells for the investigation of, 206  
 in cell cultures from liver, enzymology of, 209  
 in hepatocyte suspensions from rats (table), 210  
 regulation of, in cultured liver cells, 214  
 studies with mammalian and vertebrate liver cells, 206
- Metabolites**  
 carrier-mediated efflux, 194  
 catecholamine, lipophilicity of, 188  
 consequences of differences between the rate constants for, 195  
 distribution of, into multiple compartments, 189  
 efflux of, rate constants for (table), 190  
 of catecholamines and phenethylamines, rate constants for efflux of,  
 185  
 procedures used to measure rate constants for efflux of, 180  
 rate constants for efflux of,  
 from striatal slices (table), 194  
 of catecholamines and phenethylamines, 179  
 table, 186
- Mixed-function oxidase study, in whole cells, 231**
- Mixed-function oxidation**  
 effect of substrates for, on intermediary metabolism, 234  
 regulation of, in intact cells, 236  
 relationship with alteration in intermediary metabolism secondary to  
 acute changes in nutrition, 235
- Mutagen metabolism, regiospecificity of cytochrome P-450 in, 290**
- Mutagens, effects of, on cultured liver cells, 218**
- Nervous system**  
 adrenergic, effect on sodium reabsorption and excretion, 170  
 role of,  
 in cardiovascular effects of digitalis, 19, 52  
 in therapeutic cardiovascular actions of digitalis (table), 79  
 in toxic cardiovascular actions of digitalis, 80
- Neurotransmitters, digitalis effects on, 41**
- Nicotine, effect on hypothalamic CRF release and content in vitro  
 (fig.), 261**
- Nutrition, alteration in intermediary metabolism secondary to acute  
 changes in, relationship to mixed-function oxidation, 235**
- Opioids, effect on corticotrophin releasing factor, 267**
- Oxidase, mixed-function. See Mixed-function oxidase**
- Oxygen, effect on drug metabolism in intact hepatocytes, 236**
- Pancreas, kallikreins in, 9**
- Pentobarbitone/chlorpromazine, effect on corticotrophin releasing fac-  
 tor, 267**
- Pentobarbitone/morphine, effect on corticotrophin releasing factor, 268**
- Phenethylamines rate constants for efflux of metabolites of, 179, 185**
- Plasma, kallikrein inhibitors in, 5**
- Plasma proteins, anionic polyelectrolyte reactions with, 110**
- Polyelectrolytes, anionic**  
 chemistry of, 101  
 complexing properties of, 106  
 determination of, 108  
 heparin and, 99  
 in biology, 136  
 non-mast cell, including heparin, 149  
 reactions with plasma proteins and enzymes, 110
- Postsynaptic membranes, digitalis effect on, 52**
- Prostaglandins and renal kallikrein, 7**
- Quest, John A. See Gillis and Quest, 19**
- Rate constants**  
 for efflux of metabolites  
 consequences of differences between, 195  
 catecholamines and phenethylamines, 179, 185  
<sup>3</sup>H-dopamine from striatal slices (table), 194  
 procedures used to measure, 180  
 tables, 186, 190
- Receptor mechanisms, digitalis effect on, 51**
- Renal excretion of amine metabolites, 201**
- Renal nerve, stimulation and denervation studies, 170**
- Renin and renal kallikrein, 7**
- Reproductive physiology, kallikreins, role in, 8, 9**
- Reserpine, effect on corticotrophin releasing factor, 265**
- Salivary glands, kallikreins in, 9**
- Schachter, M. Kallikreins (kinogenases)—a group of serine proteases  
 with bioregulatory actions, 1**
- Schrier, Robert W. See Kim et al., 169**
- Serine proteases with bioregulatory actions (kallikreins), 1**
- Sirica, Alphonse E., and Henry C. Pitot. Drug metabolism and effects  
 of carcinogens in cultured hepatic cells, 205**
- Sodium pump, electrogenic, digitalis effect on, 50**
- Sodium reabsorption and excretion, effect of adrenergic nervous system  
 and catecholamines on, 170**
- Sodium transport**  
 catecholamines and, in the kidney, 169  
 in epithelial tissues, effect of catecholamines on, 174
- Sperm, kallikreins in, 9**
- Stress**  
 effect on corticotrophin releasing factor (fig.), 260  
 hypothalamo-pituitary adrenocorticotrophic activity in rats before  
 and after (fig.), 263
- Sulfation, regulation of, 242**
- Thrombosis, etiology of, related to clinical effects of heparin, 125**
- Thromboembolism, clinical effectiveness of heparin in, 126, 129**
- Toxicity of heparin, 124**
- Toxin effects, on cultured liver cells, 218**
- Trendelenburg, U., H. Bönisch, K.-H. Graefe, and M. Henseling. The  
 rate constants for the efflux of metabolites of catecholamines  
 and phenethylamines, 179**
- Vascular tone, role of nervous system in digitalis effect on, 54**

U.S. POSTAL SERVICE STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Required by 39 U.S.C. 3685)		
1. TITLE OF PUBLICATION <b>PHARMOCOLOGICAL REVIEWS</b>	2. PUBLICATION NO. 4 2 9 1 5 6 0	3. DATE OF FILING 10/1/80
4. FREQUENCY OF ISSUE Quarterly	A. NO. OF ISSUES PUBLISHED ANNUALLY 4	B. ANNUAL SUBSCRIPTION PRICE \$20.00
4. LOCATION OF KNOWN OFFICE OF PUBLICATION (Street, City, County, State and ZIP Code) (Not printers) 428 E. Preston Street, Baltimore, MD 21202		
5. LOCATION OF THE HEADQUARTERS OR GENERAL BUSINESS OFFICES OF THE PUBLISHERS (Not printers) 428 E. Preston Street, Baltimore, MD 21202		
6. NAMES AND COMPLETE ADDRESSES OF PUBLISHER, EDITOR, AND MANAGING EDITOR		
PUBLISHER (Name and Address) Williams & Wilkins Co., 428 E. Preston Street, Balto., MD 21202		
EDITOR (Name and Address) Dr. Paul L. Munson, School of Medicine, Univ. of N. Carolina		
MANAGING EDITOR (Name and Address) Chapel Hill, NC 27514		
7. OWNER (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publication is published by a nonprofit organization, its name and address must be stated.)		
NAME	ADDRESS	
American Society for Pharmacology and Experimental Therapeutics	c/o Dr. Houston Baker 9650 Rockville Pike Bethesda, MD 20014	
8. KNOWN BONDHOLDERS, MORTGAGEES, AND OTHER SECURITY HOLDERS OWNING OR HOLDING 1 PERCENT OR MORE OF TOTAL AMOUNT OF BONDS, MORTGAGES OR OTHER SECURITIES (If there are none, so state)		
NAME	ADDRESS	
None		
9. FOR COMPLETION BY NONPROFIT ORGANIZATIONS AUTHORIZED TO MAIL AT SPECIAL RATES (Section 132.122, FPM) The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes (Check one)		
<input checked="" type="checkbox"/> HAVE NOT CHANGED DURING PRECEDING 12 MONTHS <input type="checkbox"/> HAVE CHANGED DURING PRECEDING 12 MONTHS (If changed, publisher must submit explanation of change with this statement.)		
10. EXTENT AND NATURE OF CIRCULATION	AVERAGE NO. COPIES EACH ISSUE DURING PRECEDING 12 MONTHS	ACTUAL NO. COPIES OF SINGLE ISSUE PUBLISHED NEAREST TO FILING DATE
A. TOTAL NO. COPIES PRINTED (Net Press Run)	3895	3865
B. PAID CIRCULATION 1. SALES THROUGH DEALERS AND CARRIERS, STREET VENDORS AND COUNTER SALES	None	None
2. MAIL SUBSCRIPTIONS	3144	2787
C. TOTAL PAID CIRCULATION (Sum of B1 and B2)	3144	2787
D. FREE DISTRIBUTION BY MAIL, CARRIER OR OTHER MEANS SAMPLES, COMPLIMENTARY, AND OTHER FREE COPIES	45	27
E. TOTAL DISTRIBUTION (Sum of C and D)	3189	2814
F. COPIES NOT DISTRIBUTED 1. OFFICE USE, LEFT OVER, UNACCOUNTED, SPOILED AFTER PRINTING	706	1051
2. RETURNS FROM NEWS AGENTS	None	None
G. TOTAL (Sum of E, F1 and F2—should equal net press run shown in A)	3895	3865
11. I certify that the statements made by me above are correct and complete.	SIGNATURE AND TITLE OF EDITOR, PUBLISHER, BUSINESS MANAGER, OR OWNER <i>Luan B. Rhed</i> Publisher	
12. FOR COMPLETION BY PUBLISHERS MAILING AT THE REGULAR RATES (Section 132.121, Postal Service Manual) 39 U. S. C. 3626 provides in pertinent part: "No person who would have been entitled to mail matter under former section 4359 of this title shall mail such matter at the rates provided under this subsection unless he files annually with the Postal Service a written request for permission to mail matter at such rates." In accordance with the provisions of this statute, I hereby request permission to mail the publication named in item 1 at the phased postage rates presently authorized by 39 U. S. C. 3626.		
SIGNATURE AND TITLE OF EDITOR, PUBLISHER, BUSINESS MANAGER, OR OWNER <i>Luan B. Rhed</i> Publisher		

9214-46-1 B